Novartis Ups Forecast on Lack of Diovan Competitor

July 17 (Bloomberg) -- Novartis AG raised its full-year forecast as generic competition for the Diovan blood-pressure drug failed to materialize in the U.S. Sam Fazeli reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
PBOC Will Cut Rates Sooner Rather Than Later: Neumann
35:15 - HSBC Co-Head of Asian Economic Research Frederic Neumann discusses China manufacturing PMI and what that may mean for central bank policy. He speaks with Jonathan Ferro on Bloomberg Television’s “On The Move.” (Source: Bloomberg)
  • China’s Manufacturing Miss
  • U.K. Election Not Main Concern for EU Markets: Juvyns
  • Another Self-Imposed Deadline for Greece Passes